| Literature DB >> 32033492 |
Renata Spagolla Napoleão Tavares1, Silvya Stuchi Maria-Engler2, Pio Colepicolo3, Hosana Maria Debonsi1, Monika Schäfer-Korting4, Uwe Marx5, Lorena Rigo Gaspar1, Christian Zoschke4.
Abstract
UV light catalyzes the ozone formation from air pollutants, like nitrogen oxides. Since ozone reacts with cutaneous sebum lipids to peroxides and, thus, promotes inflammation, tumorigenesis, and aging, even broad-spectrum sunscreens cannot properly protect skin. Meanwhile, xanthophylls, like fucoxanthin, proved their antioxidant and cytoprotective functions, but the safety of their topical application in human cell-based models remains unknown. Aiming for a more detailed insight into the cutaneous fucoxanthin toxicity, we assessed the tissue viability according to OECD test guideline no. 439 as well as changes in inflammation (IL-1α, IL-6, IL-8), homeostasis (EGFR, HSPB1) and metabolism (NAT1). First, we proved the suitability of our 24-well-based reconstructed human skin for irritation testing. Next, we dissolved 0.5% fucoxanthin either in alkyl benzoate or in ethanol and applied both solutions onto the tissue surface. None of the solutions decreased RHS viability below 50%. In contrast, fucoxanthin ameliorated the detrimental effects of ethanol and reduced the gene expression of pro-inflammatory interleukins 6 and 8, while increasing NAT1 gene expression. In conclusion, we developed an organ-on-a-chip compatible RHS, being suitable for skin irritation testing beyond tissue viability assessment. Fucoxanthin proved to be non-irritant in RHS and already showed first skin protective effects following topical application.Entities:
Keywords: N-acetyltransferase; antioxidants; epidermal growth factor receptor; interleukins; irritation; metabolism response; small heat and shock protein beta 1
Year: 2020 PMID: 32033492 PMCID: PMC7076544 DOI: 10.3390/pharmaceutics12020136
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Primer sequences for PCR studies.
| Gene Name | Used Primer Sequence | |
|---|---|---|
| Forward | Reverse | |
|
| CCACCATGTACCCTGGCATT | GCTTGCTGATCCACATCTGCT |
|
| GCCGACAGCTATGAGATGGAG | TGGAGGTGCAGTTTTTGAAGTG |
|
| GACCCCACCCAAGTTTCCTC | TCGGATTTTGCAGCTTCTGG |
|
| GTGACTGCCCAAGATGAAGACC | TGCCAAGCACACCCAGTAGTC |
|
| CTGGATCAGGACTTTTGTACTCATCT | CCAATCTGGATTCAATGAGGAGACT |
|
| GTGGAGAAGTTTTTGAAGAGGGC | TCTGGCAACCCTACAACAGAC |
|
| ATCCGAGCTGTTCCCTTTGAG | AACATACCCTCCCAACATCGTG |
Figure 1Morphology and protein expression in reconstructed human skin. (a) Hematoxylin-eosin staining showing all layers of human skin. (b) Immunolocalization of keratin-10 (green) in suprabasal epidermal layers and keratin-14 (red) in all epidermal layers. (c) Immunolocalization of involucrin (green), indicating terminal keratinocyte differentiation. Images are representative of three batches; nuclei in blue (DAPI); scale bars = 100 µm.
Figure 2Morphology and protein expression in reconstructed human skin following fucoxanthin exposure versus the vehicles alone. (a–c) Hematoxylin-eosin staining with slightly disturbed morphology in c. (d–f) Immunolocalization of filaggrin with enhanced expression in d and f. (g–i) Similar immunolocalization of involucrin in all samples. Images are representative of at least three batches; nuclei in blue (DAPI); scale bars = 100 μm.
Figure 3Fucoxanthin effects on the viability of reconstructed human skin. Test substances below the 50% threshold (dashed line) are predicted to be skin irritant. PBS—phosphate buffered saline (negative control); SDS—sodium dodecyl sulfate (positive control); Fx—fucoxanthin. Alkyl benzoate and ethanol were exposed for 15 min to the RHS and subsequently washed off. Mean + SD, n ≥ 3, * p ≤ 0.05 compared to SDS.
Figure 4Fucoxanthin effects on the gene expression of reconstructed human skin. Fold change in gene expression was calculated in relation to the gene expression in reconstructed human skin exposed to the respective solvent (dashed line), SDS to PBS and Fx to alkyl benzoate or to ethanol. SDS—sodium dodecyl sulfate; PBS—phosphate-buffered saline; Fx—fucoxanthin; IL—interleukin; EGFR—epidermal growth factor receptor; HSPB1—small heat and shock protein beta 1; NAT1—N-acetyltransferase 1. Mean + SD, n = 3.